Harmony Biosciences Holdings (HRMY) Research & Development (2019 - 2025)
Harmony Biosciences Holdings (HRMY) has disclosed Research & Development for 7 consecutive years, with $49.9 million as the latest value for Q4 2025.
- Quarterly Research & Development rose 44.04% to $49.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $154.4 million through Dec 2025, up 5.9% year-over-year, with the annual reading at $189.6 million for FY2025, 30.01% up from the prior year.
- Research & Development hit $49.9 million in Q4 2025 for Harmony Biosciences Holdings, down from $55.0 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $63.6 million in Q2 2024 to a low of $4.7 million in Q1 2021.
- Historically, Research & Development has averaged $23.9 million across 5 years, with a median of $16.2 million in 2023.
- Biggest five-year swings in Research & Development: skyrocketed 324.76% in 2024 and later plummeted 76.41% in 2025.
- Year by year, Research & Development stood at $7.5 million in 2021, then skyrocketed by 35.44% to $10.1 million in 2022, then surged by 200.3% to $30.3 million in 2023, then grew by 14.39% to $34.7 million in 2024, then soared by 44.04% to $49.9 million in 2025.
- Business Quant data shows Research & Development for HRMY at $49.9 million in Q4 2025, $55.0 million in Q3 2025, and $15.0 million in Q2 2025.